PCSK9 Webinars/Videos

Key highlights from the EAS Congress 2025 focusing on new EAS consensus statement on chronic kidney metabolism, sex and gender differences in cardiovascular disease, Vesalius CV trial, PURSUIT trial, and pre/event management of LDL-C.

Professors Khalid Fayez Alhabib, Lale Tokgozoglu, and Stephen Nicholls

First published: June 24, 2025  

In this video, Prof. Maciej Banach discusses the 2024 recommendations on the optimal use of LLT in established ASCVD and following ACS.

First published: March 4, 2025  

In this video, Prof Stephen Nicholls discusses the future of ASCVD and Lipidology in 2025.

First published: February 24, 2025  

In this video, Prof. Deepak L. Bhatt presents an infographic on Proprotein Convertase Subtilisin/Kexin Type 9 in Cholesterol Homeostasis, Inflammation, and Thrombosis Associated with Cardiovascular Diseases – an overview of molecular functions and therapeutic strategies.

Prof. Deepak L. Bhatt

First published: September 10, 2024  

Prof. Chiang discusses Atherosclerotic Cardiovascular Disease (ASCVD) in context of cumulated LDL exposure, and the different stages of secondary prevention and how starting to manage the disease at a younger age or earlier stage is beneficial. At 41:12 he answers audience questions.

First published: October 25, 2023  

In recognition of the ASCVD & Lipidology Knowledge Hub 2 year anniversary, the esteemed faculty members for this educational resource site met to discuss the hot topics that have occurred over this time. Come and take a seat at this roundtable discussion with Prof. Christopher P. Cannon, Prof. Chern-En Chiang, Prof. Stephen Nicholls, Prof. S. Lale Tokgözoğlu, and Prof. Deepak Bhatt as they discuss target guidelines, dosing, and compliance in lipid lowering therapies.

The panel also discuss how showing patients’ images of their plaques help with adherence, discuss other targets such as Lp (a) and triglycerides and most importantly, discuss some of the latest data from the recently concluded ESC congress.

Prof. Christopher P. Cannon, Prof. Chern-En Chiang, Prof. Stephen Nicholls, Prof. S. Lale Tokgözoğlu, Prof. Deepak Bhatt

First published: August 1, 2023  

In this talk, Prof. Lale Tokyozoglu comprehensively summarizes the latest research and clinical updates in ASCVD and Lipidology from the last year.

Prof. Lale Tokyozoglu

First published: March 27, 2023  

In this KOL master class on demand video Prof. Samer Ellahham discusses the secondary prevention of acute coronary syndrome (ACS). He is joined by Prof. Hani Sabbour for a peer-to-peer discussion and to answer audience questions.

This interactive webinar is designed for health care professionals (cardiologists, endocrinologists, lipidologists, neurologists) who are interested in learning more on the latest research, treatment, and clinical management of patients with acute coronary syndrome.

Prof. Samer Ellahham, Prof. Hani Sabbour

First published: February 28, 2023  

Watch part one of the ESC Highlights Video. In this video Prof. Lale Tokgözoğlu summarizes some of the exciting findings that were presented in ESC 2022.

Prof. Christopher P. Cannon and Prof. S. Lale Tokgözoğlu

First published: November 1, 2022  

Watch part two of the ESC Highlights Video wherein Prof. Christopher Cannon and Prof. Lale Tokgözoğlu discuss results of some exciting trials highlighting the significance of Lp(a), PCSK9 inhibitors, patient adherence and compliance.

Prof. Christopher P. Cannon and Prof. S. Lale Tokgözoğlu

First published: November 1, 2022  

In this KOL masterclass on demand video, Prof. Stephen Nicholls will discuss the impact of intensive lipid lowering strategies (statins, evolocumab, alirocumab) on plaque phenotype and progression.

This masterclass on-demand video is designed for health care professionals (cardiologists, lipidologists, diabetes specialists, neurologists) who are interested in learning more on the results of the latest clinical trials (GLAGOV, HUYGENS, PACMAN-AMI) on coronary disease.

Prof. Stephen Nicholls

First published: July 7, 2022  

Editorial Panel Member Prof. Christopher Cannon interviews Prof. Kausik Ray, (President European Atherosclerosis Society and Professor of Public Health and Honorary Consultant Cardiologist, Imperial College London) on the program to roll out the latest PCSK9 inhibitor Inclisiran, first-in-class siRNA to lower cholesterol in the United Kingdom.

To note, the US Food and Drug Administration (FDA) recently approved Inclisiran as an add-on therapy to lower cholesterol among certain high-risk adults on maximally tolerated statin therapy.

Prof. Christopher Cannon, Prof. Kausik Ray

First published: January 10, 2022